Queen Elizabeth II Health Sciences Centre
Queen Elizabeth II Health Sciences Centre
Halifax, Nova Scotia, Canada12 results · Page 1 of 1
Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Consolidation of First-Line MRD+ Remission With Cema-cel in Patients With LBCL | B-cell neoplasm, Hemic and Lymphatic Diseases, Neoplasm, Residual, Neoplasms by Histologic Type, Neoplastic Processes, Pathologic Processes, Pathological Conditions, Signs and Symptoms, diffuse large B-cell lymphoma, immune system disorder, immunoproliferative disorder, large B-cell lymphoma, lymphatic system disorder, lymphoma, lymphoproliferative syndrome, neoplasm | Recruiting | Phase 2 | 2026-10-02 | NCT06500273 | |
| A Study of Zanubrutinib Plus Anti-CD20 Versus Lenalidomide Plus Rituximab in Participants With Relapsed/Refractory Follicular or Marginal Zone Lymphoma | B-cell neoplasm, Hemic and Lymphatic Diseases, Lymphoma, B-Cell, Marginal Zone, Neoplasms by Histologic Type, follicular lymphoma, immune system disorder, immunoproliferative disorder, lymphatic system disorder, lymphoma, lymphoproliferative syndrome, marginal zone lymphoma, neoplasm | Active, not recruiting | Phase 3 | 2026-09-28 | NCT05100862 | |
| A Study of Bleximenib, Venetoclax and Azacitidine For Treatment of Participants With Newly Diagnosed Acute Myeloid Leukemia (AML) | Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, acute myeloid leukemia, hematologic disorder, leukemia, myeloid leukemia, neoplasm | Recruiting | Phase 3 | 2026-09-25 | NCT06852222 | |
| An Open-Label Study Comparing Glofitamab and Polatuzumab Vedotin + Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone Versus Pola-R-CHP in Previously Untreated Patients With Large B-Cell Lymphoma | large B-cell lymphoma | Active, not recruiting | Phase 3 | 2026-09-11 | NCT06047080 | |
| A Phase 3 Study to Assess Efficacy and Safety of Tafasitamab Plus Lenalidomide and Rituximab Compared to Placebo Plus Lenalidomide and Rituximab in Patients With Relapsed/Refractory (R/R) Follicular Lymphoma or Marginal Zone Lymphoma. | B-cell neoplasm, Hemic and Lymphatic Diseases, Lymphoma, B-Cell, Marginal Zone, Neoplasms by Histologic Type, follicular lymphoma, immune system disorder, immunoproliferative disorder, lymphatic system disorder, lymphoma, lymphoproliferative syndrome, marginal zone lymphoma, neoplasm | Active, not recruiting | Phase 3 | 2026-09-04 | NCT04680052 | |
| A Study to Evaluate the Safety, Pharmacokinetics and Preliminary Anti-Tumor Activity of Englumafusp Alfa in Combination With Obinutuzumab and in Combination With Glofitamab Following a Pre-Treatment Dose of Obinutuzumab in Participants With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma | Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, immune system disorder, immunoproliferative disorder, lymphatic system disorder, lymphoma, lymphoproliferative syndrome, neoplasm | Active, not recruiting | Phase 1 / Phase 2 | 2026-08-27 | NCT04077723 | |
| Evaluation of Clinical Outcomes of Ponto Procedures Performed in Settings Outside the Main Operating Room (i.e. Out-of-OR) | Ear Diseases, Neurologic Manifestations, Pathological Conditions, Signs and Symptoms, Sensation Disorders, Signs and Symptoms, hearing disorder, hearing loss disorder, nervous system disorder, otorhinolaryngologic disease | Recruiting | Not stated | 2026-07-08 | NCT06930781 | |
| Oregovomab Plus Chemo in Newly Diagnosed Patients With Advanced Epithelial Ovarian Cancer Following Optimal Debulking Surgery | Abdominal Neoplasms, Adnexal Diseases, Carcinoma, Ovarian Epithelial, Digestive System Diseases, Digestive System Neoplasms, Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Genital Diseases, Neoplasms by Histologic Type, Neoplasms by Site, Peritoneal Diseases, Urogenital Diseases, Urogenital Neoplasms, carcinoma, endocrine system disorder, epithelial neoplasm, fallopian tube adenocarcinoma, fallopian tube disorder, fallopian tube neoplasm, fallopian tube serous adenocarcinoma, female reproductive system disorder, female reproductive system neoplasm, gonadal disorder, malignant endocrine neoplasm, neoplasm, ovarian cancer, ovarian disorder, ovarian serous adenocarcinoma, peritoneal carcinoma, peritoneal neoplasm, peritoneum cancer | Active, not recruiting | Phase 3 | 2026-04-01 | NCT04498117 | |
| Multiple Myeloma Molecular Monitoring Study | Blood Protein Disorders, Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, cardiovascular disorder, hematologic disorder, hemorrhagic disease, immune system disorder, immunoproliferative disorder, lymphoproliferative syndrome, monoclonal gammopathy, neoplasm, plasma cell neoplasm, vascular disorder, vascular hemostatic disease | Active, not recruiting | Not stated | 2025-06-29 | NCT03421132 | |
| ATG Plus PTCy vs ATG for CGVHD Prophylaxis | Bronchiolitis Obliterans, Hemic and Lymphatic Diseases, acute leukemia, anemia, bone marrow disorder, bronchial disorder, bronchiolitis, bronchiolitis obliterans syndrome, bronchitis, cryptogenic organizing pneumonia, graft versus host disease, hematologic disorder, immune system disorder, lung disorder, myelodysplastic syndrome, myelodysplastic syndrome with excess blasts, myelodysplastic syndrome with single lineage dysplasia, obstructive lung disease, respiratory system disorder | Active, not recruiting | Phase 2 | 2025-05-11 | NCT04202835 | |
| Critical Care Outcomes of Hematologic Oncology Patients | Hemic and Lymphatic Diseases, Neoplasms by Site, hematologic disorder, hematopoietic and lymphoid system neoplasm, neoplasm | Active, not recruiting | Not stated | 2024-11-27 | NCT03449953 | |
| Canadian Network for Autoimmune Liver Disease | Digestive System Diseases, Hepatitis, Chronic, autoimmune disease, autoimmune hepatitis, hepatitis, immune system disorder, liver disorder, primary biliary cholangitis | Recruiting | Not stated | 2021-06-07 | NCT03569826 |